These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38431099)

  • 1. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
    Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
    J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
    Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
    JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P
    Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
    Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
    Smith B; Collier MR; Wu JJ
    JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A; Marostica E; Gardiner P; Watz H; Lahu G
    Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
    Lebwohl MG; Hebert AA; Gooderham MJ
    JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
    Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR
    J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
    Snape SD; Wigger-Alberti W; Goehring UM
    Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.